Omrix Biopharmaceuticals (OMRI) Enrolls First Patient in Phase II Trials for its Fibrin Pad
More News related to JNJ
- Trading Radar for 10/14: Intel (INTC), Johnson & Johnson (JNJ), Pepsi (PEP), CSX (CSX), Genentech (DNA) Report;
- Cordis Announces New Leadership Positions in Key Business Groups
- FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
- Boston Scientific (BSX) Sell-Off Appears Unwarranted -Piper Jaffray
- Johnson & Johnson Announces Executive Appointments: Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group, and Alex Gorsky, Worldwide Chairman, Surgical Care Group
More News related to OMRI
- Unusual 11 Mid-Day Movers 10/9: PPC, HUN, NCC, MOS Higher; XL, OMRI, HMN, EYE Lower
- Omrix Biopharmaceuticals (OMRI) Suspends Fibrin Pad U.S. Phase II Clinical Trial
- Omrix Biopharmaceuticals Provides Update On Fibrin Pad U.S. Phase II Clinical Trial In Mild to Moderate Bleeding
- Omrix Biopharmaceuticals Announces Interim Analysis Indicating Superiority of Fibrin Pad Versus SURGICEL in Mild to Moderate Bleeding In U.S. Phase II Clinical Trial And Provides Update On Additional
- Omrix Biopharmaceuticals Completes Enrollment of Initial 90 Patients Needed to Conduct Interim Analysis in Fibrin Pad U.S. Phase II Clinical Trial
More News related to Corporate News
- GenCorp's Aerojet (GY) Awarded U.S. Missile Defense Agency Contract
- Epicor Software (EPIC) Board Determines Not to Pursue Elliott Associates' Proposal
- S&P Announces Change to US Index: PPS for LDG
- Law Office Announces Class Action Lawsuit Against AuthenTec (AUTH)
- Capstone Turbine (CPST) Announces New Distributor Agreement with General Detectors International
Omrix Biopharmaceuticals (NASDAQ: OMRI) enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate. This is the first clinical trial that will evaluate the Fibrin Pad's performance in surgery where severe bleeding is present and the product is applied directly onto a solid organ. The Phase II clinical trial in Israel is being conducted simultaneously with the Phase II clinical trial in the U.S., which commenced on March 27, 2008 and is under an Investigational New Drug (IND) application that was filed with the Food and Drug Administration (FDA) in November 2007.
The Fibrin Pad is a breakthrough convergence product candidate comprised of biological components in a biodegradable device. In collaboration with ETHICON, INC., a Johnson & Johnson company (NYSE: JNJ), the Fibrin Pad is being developed for the management and rapid control of mild, moderate and severe bleeding.
Omrix Biopharmaceuticals, Inc. is a fully integrated biopharmaceutical company that develops, manufactures and markets protein-based biosurgery and passive immunotherapy products derived from human plasma by utilizing protein purification technology and manufacturing know-how. [SM]
Related Categories
Corporate NewsStocks Mentioned
+6.83Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
